Skip Nav Destination
Issues
15 December 2015
-
Cover Image
Cover Image
![issue cover]()
The cover shows an image of tricolor immunofluorescent staining of a representative tumor from a patient with pancreatic adenocarcinoma. The tissue is stained for GSK3β (red), cytokeratin 8 (green), and counterstained for DAPI. For details, see the article by Ben-Josef and colleagues on page 5612 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
20th Anniversary Commentary
CCR Translations
CCR Drug Updates
Molecular Pathways
Review
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer
Ramaswamy Govindan; Sumithra J. Mandrekar; David E. Gerber; Geoffrey R. Oxnard; Suzanne E. Dahlberg; Jamie Chaft; Shakun Malik; Margaret Mooney; Jeffrey S. Abrams; Pasi A. Jänne; David R. Gandara; Suresh S. Ramalingam; Everett E. Vokes
Cancer Therapy: Clinical
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)
Gregory N. Dietsch; Tressa D. Randall; Raphael Gottardo; Donald W. Northfelt; Ramesh K. Ramanathan; Peter A. Cohen; Kristi L. Manjarrez; Mona Newkirk; James Kyle Bryan; Robert M. Hershberg
Personalized Medicine and Imaging
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt; Alexandra Sevko; Huanhuan Jiang; Ramtin Lichtenberger; Maike Reith; Kathrin Tarnanidis; Tim Holland-Letz; Ludmila Umansky; Philipp Beckhove; Antje Sucker; Dirk Schadendorf; Jochen Utikal; Viktor Umansky
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Olivier Humbert; Jean-Marc Riedinger; Céline Charon-Barra; Alina Berriolo-Riedinger; Isabelle Desmoulins; Véronique Lorgis; Salim Kanoun; Charles Coutant; Pierre Fumoleau; Alexandre Cochet; François Brunotte
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters; Kelly S. Oliner; Timothy J. Price; Andrés Cervantes; Alberto F. Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J.A. Punt; Andrew H. Strickland; Gregory Wilson; Tudor E. Ciuleanu; Laslo Roman; Eric Van Cutsem; Pei He; Hua Yu; Reija Koukakis; Jan-Henrik Terwey; Andre S. Jung; Roger Sidhu; Scott D. Patterson
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Krishnansu S. Tewari; Michael W. Sill; Bradley J. Monk; Richard T. Penson; Harry J. Long, III; Andrés Poveda; Lisa M. Landrum; Mario M. Leitao; Jubilee Brown; Thomas J.A. Reid; Helen E. Michael; David H. Moore
Cancer Therapy: Preclinical
Author Choice
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Celina García-García; Martín A. Rivas; Yasir H. Ibrahim; María Teresa Calvo; Albert Gris-Oliver; Olga Rodríguez; Judit Grueso; Pilar Antón; Marta Guzmán; Claudia Aura; Paolo Nuciforo; Katti Jessen; Guillem Argilés; Rodrigo Dienstmann; Andrea Bertotti; Livio Trusolino; Judit Matito; Ana Vivancos; Irene Chicote; Héctor G. Palmer; Josep Tabernero; Maurizio Scaltriti; José Baselga; Violeta Serra
Author Choice
Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake
Daniela Trani; Ala Yaromina; Ludwig Dubois; Marlies Granzier; Sarah G.J.A. Peeters; Rianne Biemans; Georgi Nalbantov; Natasja Lieuwes; Brigitte Reniers; Esther E.G.C. Troost; Frank Verhaegen; Philippe Lambin
Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Minh Nguyen; Shuichi Miyakawa; Junichi Kato; Toshiyuki Mori; Toshimitsu Arai; Mark Armanini; Karen Gelmon; Rinat Yerushalmi; Samuel Leung; Dongxia Gao; Gregory Landes; Mary Haak-Frendscho; Kathleen Elias; Andrew D. Simmons
Biology of Human Tumors
SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Cheng-Yao Chiang; Chin-Chen Pan; Hong-Yi Chang; Ming-Derg Lai; Tzong-Shin Tzai; Yuh-Shyan Tsai; Pin Ling; Hsiao-Sheng Liu; Bi-Fang Lee; Hong-Ling Cheng; Chung-Liang Ho; Shu-Hui Chen; Nan-Haw Chow
Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Edgar Ben-Josef; Asha George; William F. Regine; Ross Abrams; Meredith Morgan; Dafydd Thomas; Paul L. Schaefer; Thomas A. DiPetrillo; Mitchel Fromm; William Small, Jr; Samir Narayan; Kathryn Winter; Kent A. Griffith; Chandan Guha; Terence M. Williams
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Harrison Tsai; Carlos L. Morais; Mohammed Alshalalfa; Hsueh-Li Tan; Zaid Haddad; Jessica Hicks; Nilesh Gupta; Jonathan I. Epstein; George J. Netto; William B. Isaacs; Jun Luo; Rohit Mehra; Robert L. Vessella; R. Jeffrey Karnes; Edward M. Schaeffer; Elai Davicioni; Angelo M. De Marzo; Tamara L. Lotan
Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients
Monique C. de Jong; Jelle J. ten Hoeve; Reidar Grénman; Lodewyk F. Wessels; Ron Kerkhoven; Hein te Riele; Michiel W.M. van den Brekel; Marcel Verheij; Adrian C. Begg
Letters to the Editor
Acknowledgment to Reviewers
Advertisement
